FDA approves dispersible dolutegravir/abacavir/3TC for children

Simon Collins, HIV i-Base

On 30 March 2022, the US FDA approved a single tablet regimen of dolutegravir/abacavir/3TC in a dispersible formulation for children weighing 10 kgs to 25 kgs.

This will provide a simpler and easier to take option for children living with HIV.


ViiV Healthcare. ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV. (30 March 2022).

Links to other websites are current at date of posting but not maintained.